Sees FY23: Sacral neuromodulation revenue of $288.5 million, an increase of 30% compared to fiscal year 2022. Bulkamid revenue of $73.5 million, an increase of 42% compared to fiscal year 2022.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXNX:
- AXNX Earnings this Week: How Will it Perform?
- Wayfair upgraded, JD.com downgraded: Wall Street’s top analyst calls
- Axonics initiated with an Outperform at Leerink
- Axonics price target lowered to $65 from $75 at Truist
Questions or Comments about the article? Write to editor@tipranks.com